Immunocore (NASDAQ:IMCR) Stock Rating Cut to “Strong Sell” at Zacks Research

Posted by Brian Himes on Nov 11th, 2026

Zacks Research cut shares of Immunocore (NASDAQ:IMCR – Free Report) from a hold rating to a strong sell rating in a report issued on Monday,Zacks reports.

Several other equities analysts have also weighed in on the company. TD Cowen upgraded Immunocore to a “strong-buy” rating in a report on Monday, August 24th. HC Wainwright decreased their price target on Immunocore from $100.00 to $80.00 and set a “buy” rating for the company in a research note on Tuesday. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a report on Thursday, October 15th. Cantor Fitzgerald reissued an “overweight” rating on shares of Immunocore in a report on Monday, July 13th. Finally, JPMorgan Chase & Co. assumed coverage on Immunocore in a research note on Friday, August 21st. They issued an “overweight” rating and a $50.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $53.00.

Read Our Latest Report on IMCR

Immunocore Stock Up 2.0%

Immunocore stock opened at $32.38 on Monday. The company has a current ratio of 4.62, a quick ratio of 4.44 and a debt-to-equity ratio of 0.94. Immunocore has a 1-year low of $27.50 and a 1-year high of $40.71. The firm’s fifty day simple moving average is $31.46 and its 200-day simple moving average is $31.70. The company has a market capitalization of $1.67 billion, a P/E ratio of -49.81 and a beta of 0.82.

Immunocore (NASDAQ:IMCR – Get Free Report) last issued its quarterly earnings data on Friday, November 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.11). The business had revenue of $102.22 million during the quarter, compared to the consensus estimate of $152.09 million. Immunocore had a negative return on equity of 7.96% and a negative net margin of 7.48%. Sell-side analysts forecast that Immunocore will post -0.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of IMCR. Engineers Gate Manager LP grew its stake in Immunocore by 334.3% in the 2nd quarter. Engineers Gate Manager LP now owns 60,327 shares of the company’s stock valued at $1,915,000 after buying an additional 46,435 shares during the last quarter. Braidwell LP bought a new position in Immunocore in the 2nd quarter worth $16,552,000. Eversept Partners LP acquired a new position in Immunocore during the 1st quarter worth $1,183,000. Public Employees Retirement System of Ohio acquired a new position in Immunocore during the 2nd quarter worth $2,145,000. Finally, Stempoint Capital LP acquired a new position in Immunocore during the 1st quarter worth $1,916,000. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Immunocore News Roundup

Here are the key news stories impacting Immunocore this week:

Positive Sentiment: Shares crossed above their 200-day moving average, a potentially supportive technical signal, despite the earnings miss referenced in the report. Immunocore shares cross above 200-day moving average
Positive Sentiment: HC Wainwright maintained its Buy rating and an $80 price target—about 147% above the cited $32.38 share price—though the target was reduced from $100. HC Wainwright rating and price target
Neutral Sentiment: Immunocore presented at the Society for Immunotherapy of Cancer’s 2026 annual meeting; the available article is a slideshow and does not detail specific new clinical findings. SITC 2026 presentation slideshow
Negative Sentiment: HC Wainwright trimmed its 2027 EPS forecasts for Q1 ($0.17 from $0.18), Q2 ($0.26 from $0.29) and full-year 2027 ($1.34 from $1.36). It raised its Q4 estimate to $0.52 from $0.49, but the overall revisions were lower.
Negative Sentiment: The cut in HC Wainwright’s price target from $100 to $80 may weigh on sentiment, even with its Buy rating retained.

Immunocore Company Profile

(Get Free Report)

Immunocore is a biotechnology company that develops T cell receptor (TCR)-based medicines for cancer and other diseases. Its ImmTAX platform is designed to create therapies that direct the body’s T cells toward targets inside cells, including targets that may be difficult for conventional antibody treatments to reach. The company’s marketed medicine, KIMMTRAK (tebentafusp-tebn), is a TCR-based therapy approved in the United States and other markets for certain patients with unresectable or metastatic uveal melanoma.